Ten-year update of ESPATUE in 161 patients with resectable stage III NSCLC after induction therapy: overall survival was similar with surgery vs radiochemotherapy boost (29.9% vs 28.3%; p = 0.70), with comparable competing causes of death.
RCTn = 161
Eberhardt et al. Ten-year overall survival in resectable stage-III NSCLC - Results of the randomized ESPATUE trial - Long-term survival and competing risk analysis